We speculate that combination therapy have an improved effect due to the drugs acting independently on two different aspects of the disease: naproxen targets the inflammatory driver while KBP acts on the bone and cartilage structure in addition to potential intrinsic analgesic effects, thereby reducing three disease processes that may contribute to RA pain. This evidence concerns the gene KIFBP and rheumatoid arthritis.